CDKN2B-AS1 and osteosarcoma: Based on our previous analysis and the current existing evidence, we hypothesized that ANRIL may play a role in the variability of therapeutic response to cisplatin and doxorubicin and could serve as a potential clinical biomarker of therapeutic response in osteosarcoma.